Targets › PRL3
1 program from 1 company in 5 trials: 3 Phase 2, 2 Phase 1; Oncology, Ophthalmology; next expected readout Dec 2026.
Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. (UniProt, O75365)
Open in Phaseline: the race on PRL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Intra-IMMUSG Pte | PRL3-zumab Humanized monoclonal antibody targeting phosphatase of regenerating liver-3 (PRL3) | PRL3 | Phase 2 | Advanced Malignant Solid Tumor; Solid Tumor; Advanced Solid Cancers; Neovascular Age Related Macular Degeneration … | Dec 2026 |
Advanced Malignant Solid Tumor (1) Solid Tumor (1) Advanced Solid Cancers (1) Neovascular Age Related Macular Degeneration (1) Advanced Solid Tumors (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.